Gentian Diagnostics ASA
OSE:GENT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.8
59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Gentian Diagnostics ASA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | NO |
| Market Cap | 629.2m NOK |
| Net Margin |
-1%
|
| Country | JP |
| Market Cap | 6.8T JPY |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.9B CHF |
| Net Margin |
12%
|
| Country | DK |
| Market Cap | 200.9B DKK |
| Net Margin |
19%
|
| Country | US |
| Market Cap | 16.9B USD |
| Net Margin |
11%
|
| Country | KR |
| Market Cap | 9.9T KRW |
| Net Margin |
-358%
|
| Country | CA |
| Market Cap | 6.9B USD |
| Net Margin |
-8%
|
| Country | CN |
| Market Cap | 48.6B CNY |
| Net Margin |
42%
|
| Country | US |
| Market Cap | 6.3B USD |
| Net Margin |
29%
|
| Country | US |
| Market Cap | 6.1B USD |
| Net Margin |
9%
|
| Country | UK |
| Market Cap | 4.8B GBP |
| Net Margin |
7%
|
Gentian Diagnostics ASA
Glance View
Gentian Diagnostics ASA is a medical diagnostics company. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Gentian Diagnostics ASA's most recent financial statements, the company has Net Margin of -1.4%.
You don't have any saved screeners yet
